KEY TAKEAWAYS |
• Choose a gastric cancer multidisciplinary team, not a hospital name alone. Ask who will review pathology, staging, surgery and drug treatment together. • Stage and biomarkers guide care. HER2, PD-L1, MSI/MMR and CLDN18.2 results may influence systemic treatment discussions. • China-based trials have reported advances, but trial results do not guarantee eligibility, routine availability or benefit for an individual patient. • Prepare translated records, confirm the campus and clinician, and obtain an itemized estimate and follow-up plan before arranging travel. |
Introduction
Looking for the best stomach cancer hospital in China? Peking University Cancer Hospital in Beijing, Fudan University Shanghai Cancer Center in Shanghai, and Sun Yat-sen University Cancer Center in Guangzhou are three specialist centers worth discussing with your treating team. Each has documented gastric cancer expertise, but the right choice depends on your diagnosis, stage, treatment history and ability to travel.
This is an unranked shortlist, not a claim that one hospital is best for every patient. The guide focuses mainly on gastric adenocarcinoma; stomach lymphoma, gastrointestinal stromal tumors and other uncommon diagnoses need different specialist pathways. Hospital and doctor information was checked against institutional sources for this 2026 draft.
Table of Contents
Stomach cancer treatment in China: what has advanced?
Treatment planning begins with the exact pathology and stage. Selected very early tumors may be considered for endoscopic removal. Operable disease can require gastrectomy with lymph-node surgery and chemotherapy before or after the operation. Unresectable or metastatic disease usually calls for systemic treatment and supportive care; radiotherapy has a role in selected situations. Your team should explain the treatment goal and alternatives before recommending a procedure.
For advanced gastric adenocarcinoma, ask whether adequate tissue has been tested for HER2, PD-L1, mismatch-repair deficiency or microsatellite instability, and CLDN18.2. These results can help guide chemotherapy, immunotherapy or targeted-treatment choices. A positive marker is only part of the decision: previous treatment, general health, toxicity and local access still matter. International guidance does not prove that a particular drug is available at every Chinese hospital.
Nutrition deserves attention from the start. Ask how the team will address weight loss, swallowing or eating difficulty, anemia and recovery after surgery. Treatment should include a plan for symptom control and practical support, alongside cancer-directed therapy.
Clinical evidence: two China-based studies and their limits
DRAGON IV/CAP 05, a randomized phase III study reported online in 2024 and in the Journal of Clinical Oncology in 2025, examined perioperative treatment for locally advanced gastric or gastroesophageal-junction adenocarcinoma. Its reported analysis compared 180 patients receiving camrelizumab, low-dose rivoceranib and S-1/oxaliplatin with 180 receiving chemotherapy alone. Pathologic complete response was 18.3% versus 5.0%. Grade 3 or higher treatment-related adverse events during preoperative therapy occurred in 34% versus 17%.
This result concerns the response found in surgically removed tissue. It is not a cure rate, and this pathologic-response report alone does not establish a long-term survival advantage. The added drugs also increased serious treatment toxicity. Ask whether a proposed regimen is standard care for your situation or part of a research protocol.
The 2025 Lancet CT041-ST-01 phase II trial randomized 156 patients in China with CLDN18.2-positive advanced gastric or gastroesophageal-junction cancer after at least two prior treatment lines. Median progression-free survival was 3.25 months with satri-cel, a CAR T-cell treatment, versus 1.77 months with physician-selected treatment. Among treated patients, grade 3 or higher treatment-emergent adverse events occurred in 99% versus 63%; cytokine-release syndrome occurred in 95% of those receiving satri-cel.
These findings describe a selected, heavily pretreated population, not first-line treatment for all stomach cancers. That trial is closed to new patients. Its publication does not establish current routine availability or access for overseas patients; a hospital must confirm the regulatory pathway, any open study, eligibility, monitoring requirements and total costs.
Why international patients consider China—and what to confirm
Specialist gastric surgery teams, dedicated gastrointestinal oncology departments and participation in clinical research are reasons to consider an assessment in China. The useful comparison is the proposed care plan: how the team establishes stage, selects treatment, manages complications and coordinates recovery. A robotic operation or a new drug is not automatically better for a particular patient.
Before travel, send the pathology report and, when requested, slides or tissue blocks; endoscopy and biopsy reports; imaging reports and original DICOM scans; laboratory results; prior surgery and chemotherapy records; biomarker reports; current medicines; allergies; and a short clinical timeline. Confirm which records need Chinese or English translation and whether repeat biopsy or testing may be necessary.
Ask the hospital to confirm the correct campus, appointment route, named department and whether the case can first be reviewed remotely. An English-language website does not guarantee an English-speaking clinical team. Arrange qualified interpretation, including consent discussions, discharge instructions and emergency communication.
Obtain an itemized estimate covering consultation, pathology review, staging, medicines, surgery if relevant, admission, complication management and follow-up. Also budget for accommodation, interpretation and caregiver travel. This guide does not quote a treatment price because the diagnosis and plan have not been assessed; insurance coverage, payment rules and drug access must be confirmed individually.
Your treating clinician should assess fitness for travel. Agree who will supervise care after returning home, how scans and pathology will be shared, and where urgent complications will be managed. Do not interrupt effective treatment while waiting for an overseas opinion.
How ChinaCureLink can help organize an assessment
ChinaCureLink can help organize records, translation needs and appointment questions for a hospital assessment. The hospital's clinicians determine diagnosis, eligibility and treatment. Coordination does not guarantee admission, access to a named professor, a clinical trial place or a particular outcome. Ask for the scope and fees of any coordination service in writing.
Three stomach cancer hospitals in China and relevant specialists
The order below is geographic and editorial, not a ranking. Doctor profiles identify documented areas of practice; they do not imply endorsement, partnership or confirmed appointment availability.
Peking University Cancer Hospital & Institute — Beijing
Founded in 1976, Peking University Cancer Hospital, also known as Beijing Cancer Hospital, is a university-affiliated specialist cancer hospital. Its official overview identifies a flagship Gastrointestinal Cancer Center and multidisciplinary care across surgery, medical oncology, pathology and other cancer services. This makes it a relevant center to consider when a gastric cancer case needs both surgical and systemic-treatment opinions.
The specific reason to consider this center is its documented combination of gastric surgical expertise and gastrointestinal drug-development research. An assessment could address whether the cancer is operable, whether treatment should precede surgery, and which pathology or biomarker results need review. These are case-dependent questions, not promises of access to a particular therapy.
Before choosing Beijing, confirm the department and campus, interpretation arrangements, pathology-transfer requirements and whether a joint surgical/medical oncology review can be arranged. Ask for a written recommendation that can be discussed with your home oncologist.
Professor Jiafu Ji
Chief Physician and Professor — Gastrointestinal Tumor Center
Professor Ji's institutional profile documents a focus on multidisciplinary gastric cancer treatment, gastric surgery, perioperative chemotherapy and translational research. His expertise is relevant to reviewing an operable or potentially operable gastric cancer case, including how surgery fits within the overall treatment plan. Appointment availability and personal case acceptance require confirmation.
Professor Lin Shen
Chief Physician and Professor — Gastrointestinal Oncology
Professor Shen's official profile identifies leadership in gastrointestinal oncology and the phase I clinical unit, with interests in precision treatment, translational research and new-drug trials. Her work is relevant to complex systemic-treatment discussions. A research interest does not establish that a suitable study is open or that an overseas patient will qualify.
Fudan University Shanghai Cancer Center — Shanghai
Fudan University Shanghai Cancer Center is a specialist academic cancer hospital with Xuhui and Pudong campuses. Its institutional information describes multidisciplinary services, while the gastric surgery profiles below document a dedicated focus on stomach cancer operations and multimodal care. The campus and surgical unit should be confirmed when requesting an appointment.
This center is particularly relevant to a discussion about gastric or gastroesophageal-junction surgery, including whether minimally invasive surgery is appropriate. The important questions are whether surgery is advisable now, whether treatment should come first, what extent of resection is proposed and how recovery and nutrition will be supported.
Ask for review of the original endoscopy, biopsy and imaging rather than choosing an operation solely by technique. Laparoscopic and robotic approaches require patient selection and experienced teams; they do not eliminate the risks of gastrectomy or the possible need for systemic therapy.
Professor Hua Huang
Chief Physician and Professor — Gastric Surgery
Professor Huang's Fudan profile lists gastric and cardia cancer surgery, laparoscopic and robotic approaches, and conversion treatment for selected advanced gastric cancers among his interests. His documented focus supports a surgical assessment, including discussion of alternatives and timing. Conversion treatment is not a promise that an initially unresectable cancer will become operable.
Professor Dazhi Xu
Chief Physician and Professor — Gastric Surgery
Professor Xu is identified as a Fudan gastric surgery specialist in an official medical-consortium hospital profile and appears in Fudan's expert clinic listings. His stated interests include laparoscopic gastric cancer surgery and perioperative recovery. He is also an author of the DRAGON IV report; this does not imply that its regimen is appropriate or available for every patient.
Sun Yat-sen University Cancer Center — Guangzhou
Sun Yat-sen University Cancer Center is a comprehensive specialist oncology institution established in 1964. Its official information describes clinical, research and teaching services, with an international medical center and dedicated gastrointestinal oncology expertise. For an international patient, the relevant starting point is the department that can review the exact diagnosis and prior treatment.
This is a useful option to consider for multidisciplinary assessment and complex gastrointestinal medical oncology questions, including biomarker-directed treatment and subsequent-line options. Its research activity should be considered alongside routine care, toxicity management and the feasibility of returning for repeated visits.
Confirm the campus and international-patient route before making travel arrangements. Ask which tests will be repeated, who will provide the clinical plan, how interpreter support is organized and how treatment records will be transferred to your home team. Neither an institutional research program nor a published study guarantees trial enrollment.
Professor Ruihua Xu
Professor and Medical Oncologist — Gastrointestinal Cancers
Professor Xu's institutional profiles describe leadership at the cancer center and a research focus on gastrointestinal cancers, precision treatment and immunotherapy. His work includes gastric cancer clinical research. Patients considering an opinion should ask which member of the gastrointestinal oncology team will review the records and whether the consultation concerns routine treatment or a specific study.
Professor Yu-hong Li
Professor and Chief Physician — Medical Oncology
Professor Li's official English profile lists gastrointestinal cancers, including gastric cancer, among her clinical interests. It describes chemotherapy, targeted therapy and immunotherapy expertise, alongside a substantial colorectal cancer research focus. Her profile is relevant to a gastrointestinal medical oncology assessment; suitability for a specific stomach cancer case should be confirmed with the department.
Get a Second Opinion Before You Fly to China
Before committing to travel, ask whether a specialist can review your records remotely. For suitable cases, ChinaCureLink can help coordinate a second-opinion request to clarify the proposed treatment, questions for the clinical team and the records still needed. The hospital must confirm availability and suitability.
The following patient stories and feedback describe general coordination experiences. They are not stomach cancer outcome evidence and do not predict an individual result.
What Patients Say About ChinaCureLink & Medebound HEALTH
ChinaCureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
FAQs about stomach cancer hospitals in China
Which is the best stomach cancer hospital in China?
There is no single best hospital for every patient. Peking University Cancer Hospital, Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center are three specialist options to assess. Compare their proposed plan for your cancer type, stage and treatment history, along with language support, costs and follow-up arrangements. This guide is an unranked shortlist.
Can international patients receive advanced stomach cancer treatment in China?
An international patient may be considered for assessment, but the hospital must confirm acceptance, diagnosis, fitness and the availability of the proposed treatment. Biomarker results and prior therapies affect eligibility. A published clinical trial does not guarantee access, and CT041-ST-01 is closed to new patients. Confirm any current trial or regulatory pathway directly before travel.
What records should I send for a gastric cancer hospital assessment?
Prepare pathology and biomarker reports, endoscopy findings, imaging reports and original scans, prior treatment records, current medicines, allergies and a clinical timeline. The hospital may request tissue or slides and translated documents. Obtain a written estimate and a plan for interpretation, travel fitness and follow-up with your home oncology team.
Prepare your next step
For help organizing records and hospital-assessment questions, contact ChinaCureLink. Share your diagnosis, stage, treatment timeline and available reports so the coordination request is specific. Your clinical team should guide urgent care and treatment decisions.
Sources and further reading
Information checked for this draft on October 30, 2026. Clinical practice, services, doctors' schedules and trial availability can change. Images identify the institutions or clinicians shown and do not imply a commercial affiliation.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
